Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma

Editor Note: For more information about this release, please scroll to bottom.

LONDON, October 20, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 17, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,380.41, up 1.63% and the NASDAQ Composite closed at 4,258.44, up 0.97%. The S&P 500 finished the session 1.29% higher at 1,886.76. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index advancing 10.21% on YTD basis. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

Amgen Inc.'s stock gained 2.48%, to close the day at $133.69. The stock recorded a trading volume of 7.35 million shares, much above its three months average volume of 3.48 million shares. The company's shares oscillated between $129.50 and $139.85 during the session. Over the last three trading sessions and over the past three months, Amgen Inc.'s shares have advanced 1.13% and 13.01%, respectively. Further, the stock has gained 17.19% since the start of this year. The stock is trading above its 200-day moving average of $123.48, while the 200-day moving average is below its 50-day moving average of $136.50. Additionally, the stock traded at a PE ratio of 19.98 and has a Relative Strength Index (RSI) of 44.09. Sign up and read the free notes on AMGN at:

www.Investor-Edge.com/AMGN-20Oct2014

On Friday, shares in Exelixis Inc. recorded a trading volume of 1.29 million shares, lower than its three months average volume of 4.57 million shares. The stock ended the day at $1.58, which was 2.78% below its previous day's closing of $1.62, and registered an intraday range of $1.55 and $1.68. Although Exelixis Inc.'s stock has advanced 3.62% in the previous three trading sessions, it has lost 7.35% in the last one month and 74.31% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $2.45 and $4.26, respectively. Furthermore, shares of Exelixis Inc. have an RSI of 35.26. The complimentary notes on EXEL can be downloaded as in PDF format at:

www.Investor-Edge.com/EXEL-20Oct2014

Regeneron Pharmaceuticals Inc.'s stock rallied 8.49% to end Friday's session at $369.64, hitting a new 52-week high of $376.88. The stock recorded a trading volume of 2.47 million shares, much above its three months average volume of 0.78 million shares. The company's shares fluctuated between $362.02 and $376.88 during the session. Shares of the company traded at a PE ratio of 103.08. Regeneron Pharmaceuticals Inc.'s shares have gained 34.30% since the beginning of 2014. Further, the stock has advanced 12.67% over the previous three trading sessions and 20.83% in the last three months. The stock is trading above its 50-day and 200-day moving averages. The company's shares 50-day moving average of $350.77 is above its 200-day moving average of $315.95. Additionally, the stock has an RSI of 60.52. On the same day, Regeneron Pharmaceuticals Inc. announced that in the National Institutes of Health sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T), EYLEA® injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity from baseline at 52 weeks compared to Genentech's Avastin® and Lucentis® injections. Register for free on Investor-Edge and access the latest research on REGN at:

www.Investor-Edge.com/REGN-20Oct2014

On Friday, shares in Lexicon Pharmaceuticals Inc. fluctuated between $1.26 and $1.35 before ending the session 1.50% lower at $1.31. The stock reported a trading volume of 1.11 million shares, higher than its three months average volume of 0.86 million shares. Lexicon Pharmaceuticals Inc.'s shares have rallied 21.30% in the previous three trading sessions, while the stock has lost 8.39% in the last one month and 27.18% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $1.43 and $1.60, respectively. Moreover, shares of Lexicon Pharmaceuticals Inc. have an RSI of 48.78. The complete research on LXRX is available for free at:

www.Investor-Edge.com/LXRX-20Oct2014

BioMarin Pharmaceutical Inc.'s stock finished Friday's session 0.20% lower at $70.45. A total of 1.76 million shares were traded, which was above its three months average volume of 1.14 million shares. The stock vacillated between $70.03 and $71.53 during the session. Over the previous three trading session and over the last one month, BioMarin Pharmaceutical Inc.'s shares have advanced 4.73% and 0.86%, respectively. Additionally, the stock has gained 19.29% in the past three months. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $69.38 is greater than its 200-day moving average of $66.75. BioMarin Pharmaceutical Inc.'s stock has an RSI of 52.18. Free in depth research on BMRN is available at:

www.Investor-Edge.com/BMRN-20Oct2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.